Roche Holding AG

Equities

ROP

CH1499059983

End-of-day quote Swiss Exchange Other stock markets 2026-06-05			5-day change	1st Jan Change
327.10 ^CHF	+0.77%		-0.67%	-0.34%

07:32pm	Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial	RE
Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE

Transcript : Roche Holding AG - Analyst/Investor Day

Published on 05/13/2026 at 01:21 am EDT - Modified on 05/18/2026 at 04:52 pm EDT

S&P Capital IQ

Presenter Speech
Bruno Eschli (Executives)

So welcome to our Annual IR Diagnostics Day 2026 here in London. Let me quickly take you through today's agenda. We have today 10 speakers with us who will

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Roche Holding AG

07:32pm	Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial	RE
Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Swiss stocks - Factors to watch on June 5	RE
Jun. 04	What Bundibugyo Ebola vaccines and treatments are under development	RE
Jun. 04	Roche chairman flags concern over U.S., China protectionism	RE
Jun. 04	Roche chairman likens US tariff policy to 'blackmail'	RE
Jun. 04	ADC Therapeutics plunges after patient deaths in blood cancer drug trial	RE
Jun. 04	Remy Cointreau cheers recovery, Universal loses its rhythm
Jun. 04	ROCHE HOLDINGS AG : Receives a Sell rating from Jefferies	ZD
Jun. 03	Ideaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer	MT
Jun. 03	Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs	RE
Jun. 03	'It's still working': More are living with cancer as era of targeted drugs takes hold	RE
Jun. 02	Swiss Stocks Close Flat; Roche Shares Down	MT
Jun. 02	Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi in Combination with Palbociclib and Fulvestrant	CI
Jun. 02	Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer	CI